중화 항체 시장 보고서(2025년)

A neutralizing antibody is a specific type of antibody that attaches directly to a virus or pathogen, effectively blocking its ability to infect host cells. Its main function is to stop infection by neutralizing the pathogen's harmful effects, thereby halting disease progression.

Neutralizing antibodies primarily come in two forms: monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-engineered molecules tailored to bind to a specific antigen, such as a virus or cancer cell. These antibodies are used to target a range of viruses, including SARS-CoV-2 (COVID-19), HIV, influenza, Ebola, Zika, and hepatitis C, among others. Distribution channels include direct sales to end-users, distributors, online retailers, and other methods. Applications span across therapeutics, diagnostics, and research and development, catering to end-users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.

The neutralizing antibody market research report is one of a series of new reports from The Business Research Company that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neutralizing antibody market size has grown rapidly in recent years. It will grow from $230.25 billion in 2024 to $257.81 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. Historical growth has been driven by a rise in biologic drug approvals, increased funding for antibody research, higher prevalence of chronic viral infections, growing awareness of immunotherapy, and expanding healthcare spending.

The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $401.16 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. This expected growth will be fueled by a rise in emerging infectious diseases, increasing autoimmune disorders, expansion of antibody-based therapy pipelines, growing demand for precision medicine, and increased interest in targeted therapies. Key trends over the forecast period include a shift toward bispecific and multispecific antibodies, the use of artificial intelligence (AI) in antibody discovery, the development of antibody-drug conjugates, increased use of plant-based antibody production, and a rise in personalized immunotherapy approaches.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one person to another either directly or indirectly. The growing incidence of these diseases is largely attributed to the rise in global travel, which enables the rapid transmission of pathogens across borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically targeting and blocking pathogens, thereby preventing the progression of illness. They contribute to improved patient outcomes by offering precise and timely immune protection. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, up by 10.7% from 4,380 cases in 2022. This highlights how the rising prevalence of infectious diseases is bolstering the neutralizing antibody market.

Leading companies in the neutralizing antibody market are prioritizing the development of advanced therapies, including targeted treatments, to more effectively combat infectious diseases by directly neutralizing viruses and preventing their entry into human cells. Targeted therapies are designed to act on specific molecular markers or pathways that are essential for the growth and survival of disease-causing cells, such as those involved in cancers or viral infections. For instance, in February 2022, Eli Lilly and Company, a U.S.-based pharmaceutical firm, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a neutralizing monoclonal antibody therapy aimed at treating COVID-19. Bebtelovimab is intended for use in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death. This approval supports timely treatment efforts amid the emergence of new viral variants, thereby aiding in the reduction of disease severity and enhancement of patient outcomes.

In July 2022, Brii Biosciences Limited, a biotechnology firm based in China, collaborated with China Resources Pharmaceutical Commercial Group Co., Ltd. through its joint venture, TSB Therapeutics (Beijing) Co. Ltd., to support the commercialization of amubarvimab/romlusevimab in China. This partnership is focused on expanding access to the treatment for patients with mild to moderate COVID-19 who are at risk of developing severe illness, and accelerating its availability across the country. China Resources Pharmaceutical Commercial Group Co., Ltd. is engaged in the distribution of neutralizing antibody products within China.

Major players in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, and AXIM Biotechnologies.

North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neutralizing antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neutralizing Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neutralizing antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neutralizing antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutralizing antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Antibody Type: Monoclonal Antibodies; Polyclonal Antibodies
• 2) By Target Virus: SARS-CoV-2 (COVID-19); Human Immunodeficiency Viruses (HIV); Influenza; Ebola; Zika; Hepatitis C; Other Target Viruses
• 3) By Distribution Channel: Direct Sales To End-Users; Distributors; Online Retail; Other Distribution Channels
• 4) By Application: Therapeutics; Diagnostics; Research And Development
• 5) By End User: Hospitals And Clinics; Research Institutes; Diagnostic Laboratories; Pharmaceutical Companies; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies; Recombinant Polyclonal Antibodies; Human Polyclonal Antibody Preparations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neutralizing Antibody Market Characteristics

3. Neutralizing Antibody Market Trends And Strategies

4. Neutralizing Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neutralizing Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neutralizing Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neutralizing Antibody Market Growth Rate Analysis
• 5.4. Global Neutralizing Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neutralizing Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neutralizing Antibody Total Addressable Market (TAM)

6. Neutralizing Antibody Market Segmentation

• 6.1. Global Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• 6.2. Global Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SARS-CoV-2 (COVID-19)
• Human Immunodeficiency Viruses (HIV)
• Influenza
• Ebola
• Zika
• Hepatitis C
• Other Target Viruses
• 6.3. Global Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales To End-Users
• Distributors
• Online Retail
• Other Distribution Channels
• 6.4. Global Neutralizing Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutics
• Diagnostics
• Research And Development
• 6.5. Global Neutralizing Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Other End Users
• 6.6. Global Neutralizing Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fully Human Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Murine Monoclonal Antibodies
• 6.7. Global Neutralizing Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Animal-Derived Polyclonal Antibodies
• Recombinant Polyclonal Antibodies
• Human Polyclonal Antibody Preparations

7. Neutralizing Antibody Market Regional And Country Analysis

• 7.1. Global Neutralizing Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neutralizing Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neutralizing Antibody Market

• 8.1. Asia-Pacific Neutralizing Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neutralizing Antibody Market

• 9.1. China Neutralizing Antibody Market Overview
• 9.2. China Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neutralizing Antibody Market

• 10.1. India Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neutralizing Antibody Market

• 11.1. Japan Neutralizing Antibody Market Overview
• 11.2. Japan Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neutralizing Antibody Market

• 12.1. Australia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neutralizing Antibody Market

• 13.1. Indonesia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neutralizing Antibody Market

• 14.1. South Korea Neutralizing Antibody Market Overview
• 14.2. South Korea Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neutralizing Antibody Market

• 15.1. Western Europe Neutralizing Antibody Market Overview
• 15.2. Western Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neutralizing Antibody Market

• 16.1. UK Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neutralizing Antibody Market

• 17.1. Germany Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neutralizing Antibody Market

• 18.1. France Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neutralizing Antibody Market

• 19.1. Italy Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neutralizing Antibody Market

• 20.1. Spain Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neutralizing Antibody Market

• 21.1. Eastern Europe Neutralizing Antibody Market Overview
• 21.2. Eastern Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neutralizing Antibody Market

• 22.1. Russia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neutralizing Antibody Market

• 23.1. North America Neutralizing Antibody Market Overview
• 23.2. North America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neutralizing Antibody Market

• 24.1. USA Neutralizing Antibody Market Overview
• 24.2. USA Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neutralizing Antibody Market

• 25.1. Canada Neutralizing Antibody Market Overview
• 25.2. Canada Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neutralizing Antibody Market

• 26.1. South America Neutralizing Antibody Market Overview
• 26.2. South America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neutralizing Antibody Market

• 27.1. Brazil Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neutralizing Antibody Market

• 28.1. Middle East Neutralizing Antibody Market Overview
• 28.2. Middle East Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neutralizing Antibody Market

• 29.1. Africa Neutralizing Antibody Market Overview
• 29.2. Africa Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neutralizing Antibody Market Competitive Landscape And Company Profiles

• 30.1. Neutralizing Antibody Market Competitive Landscape
• 30.2. Neutralizing Antibody Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Neutralizing Antibody Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. GeNext Genomics
• 31.6. Celltrion Healthcare Co. Ltd
• 31.7. BeiGene Ltd
• 31.8. AbCellera Biologics Inc.
• 31.9. BMC Pharmacology and Toxicology
• 31.10. Anthos Therapeutics
• 31.11. Immunome Inc.
• 31.12. Sorrento Therapeutics Inc.
• 31.13. Tonix Pharmaceuticals
• 31.14. Abwiz Bio
• 31.15. AXIM Biotechnologies

32. Global Neutralizing Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neutralizing Antibody Market

34. Recent Developments In The Neutralizing Antibody Market

35. Neutralizing Antibody Market High Potential Countries, Segments and Strategies

• 35.1 Neutralizing Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neutralizing Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neutralizing Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer